John Dawson appointed Senior Independent Director

Ergomed

02/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221202:nRSB3547Ia&default-theme=true

RNS Number : 3547I  Ergomed plc  02 December 2022

 PRESS RELEASE

 

 

John Dawson CBE Appointed Senior Independent Director

 

 

Guildford, UK - 2 December 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, today announces that John Dawson, CBE has been
appointed Senior Independent Director of the Board with immediate effect. Mr
Dawson has served as an independent Non-Executive Director and Chair of the
Audit Committee of the Ergomed Board of Directors since March 2022.

 

 

 

ENDS

 

Enquiries:

 

 Ergomed plc                                                                 Tel: +44 (0) 1483 402 975
 Miroslav Reljanović (Executive Chairman)
 Richard Barfield (Chief Financial Officer)

 Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

 Numis (Nominated Advisor and Joint Broker)                                 Tel: +44 (0) 20 7260 1000
 Freddie Barnfield / Euan Brown (Nominated Adviser)
 James Black (Broker)

 Peel Hunt LLP (Joint Broker)                                                  Tel: +44 (0) 20 7418 8900

 James Steel / Dr Christopher
 Golden

 Consilium Strategic Communications - for UK enquiries                      Tel: +44 (0) 20 3709 5700
 Chris Gardner / Matthew Neal                                               ergomed@consilium-comms.com
                                                                            (https://consiliumsc.sharepoint.com/sites/Clients/Shared%20Documents/Ergomed/Press%20releases/2022/Drafts/2202%20Notice%20of%20Results/ergomed@consilium-comms.com)
 Angela Gray

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOATBBBTMTTMTMT